Sulforaphane
Sulforaphane is an isothiocyanate produced when glucoraphanin in cruciferous vegetables, particularly broccoli sprouts, is hydrolyzed by the enzyme myrosinase upon cell disruption; it is the most potent naturally occurring activator of the NRF2 transcription factor, inducing a broad cytoprotective gene expression program that encompasses phase 2 detoxification enzymes, antioxidant defenses, and anti-inflammatory pathways, with documented activity as an HDAC inhibitor that can reactivate silenced tumor suppressor genes in cancer models.
Key Takeaways
- •Sulforaphane is the most potent natural activator of the NRF2 (NFE2L2) transcription factor; it modifies cysteine residues on KEAP1 to disrupt the KEAP1-NRF2 interaction, allowing NRF2 to accumulate in the nucleus and activate over 200 cytoprotective target genes including NQO1, HMOX1, GST, and TXNRD1.
- •Broccoli sprout extracts standardized to sulforaphane content are approximately 50 to 100 times more concentrated in glucoraphanin than mature broccoli florets, making sprout-based supplements the most practical delivery vehicle for pharmacological sulforaphane doses.
- •Sulforaphane inhibits class I and II HDACs (histone deacetylases), producing epigenetic reactivation of silenced tumor suppressor genes including CDH1 (E-cadherin), CDKN1A (p21), and RB1; this HDAC inhibitory activity is distinct from and complementary to its NRF2 activation mechanism.
- •NQO1 (NAD(P)H:quinone oxidoreductase 1) induction by sulforaphane is among the most robust and reproducible effects in the human clinical literature; sulforaphane raises NQO1 activity in blood mononuclear cells and tissue biopsies at doses achievable through broccoli sprout consumption.
- •As a mild hormetic stressor, sulforaphane activates HSF1, the master regulator of the heat shock response, priming the cellular chaperone network for subsequent proteotoxic stress; this positions sulforaphane as both an inducer of the antioxidant response and an activator of the proteostasis maintenance program.
- •The p62-KEAP1-NRF2 positive feedback loop, in which sulforaphane-induced NRF2 activates SQSTM1/p62 expression, and p62 in turn sequesters KEAP1 to further amplify NRF2 activity, means that the NRF2 response to sulforaphane is self-amplifying and sustained well beyond the compound half-life.
- •Human clinical trials with broccoli sprout extracts have confirmed NRF2 target gene induction, reduced urinary aflatoxin-DNA adducts, reduced airway inflammation in asthma, and reduced carcinogen-DNA adduct formation in smokers, establishing a translational evidence base for the mechanistic predictions.
- •Cooking destroys myrosinase, the enzyme required to convert glucoraphanin to sulforaphane; supplementing with myrosinase (or gut bacterial conversion) or consuming raw/lightly steamed sprouts is necessary to maximize bioavailability from food sources.
Basic Information
- Name
- Sulforaphane
- Also Known As
- 1-isothiocyanato-4-(methylsulfinyl)butanebroccoli sprout extractglucoraphanin (precursor)SGS (sulforaphane glucosinolate)BSE (broccoli sprout extract)
- Category
- Isothiocyanate / NRF2 activator / HDAC inhibitor
- Bioavailability
- Bioavailability is highly dependent on the source and preparation. From raw broccoli sprouts with intact myrosinase, bioavailability of sulforaphane is high (approximately 37 percent of glucoraphanin converted). Glucoraphanin-only supplements without co-delivered myrosinase rely entirely on gut bacterial conversion, which is variable and often incomplete (less than 10 percent conversion in some individuals). Stabilized sulforaphane or myrosinase-co-delivered supplements provide more consistent absorption. Peak plasma levels occur 1 to 2 hours after dosing. Food slows absorption but does not substantially reduce total bioavailability.
- Half-Life
- Plasma half-life of sulforaphane is approximately 2 to 3 hours. However, the biological effects (NRF2 target gene induction) persist for 24 to 72 hours after a single dose due to the self-amplifying NRF2/p62/KEAP1 feedback loop. Once daily dosing is therefore sufficient for sustained NRF2 pathway activation despite the short sulforaphane half-life.
Primary Mechanisms
KEAP1 cysteine modification releasing NRF2 from proteasomal degradation, enabling NRF2 nuclear accumulation
NRF2-driven transcriptional activation of phase 2 detoxification and antioxidant genes (NQO1, HMOX1, GCLC, TXNRD1)
Class I and II HDAC inhibition with epigenetic reactivation of silenced tumor suppressor genes
HSF1 activation as a mild hormetic stressor, priming the heat shock response and chaperone network
NF-kappaB inhibitory cross-talk through NRF2, reducing pro-inflammatory cytokine transcription
p62-KEAP1-NRF2 positive feedback loop amplification of the antioxidant response
Induction of glutathione S-transferases that conjugate and eliminate electrophilic carcinogens
Quick Safety Summary
Clinical trials have used 10 to 40 mg sulforaphane per day (equivalent to approximately 200 to 400 mg broccoli sprout extract standardized to 10 percent sulforaphane). Glucoraphanin doses of 50 to 200 mg per day have been used in longer trials. Short-term doses up to 200 mg sulforaphane equivalent per day have been well tolerated. Most trials are 1 to 12 weeks; long-term safety data beyond 6 months at high doses is limited.
Individuals on anticoagulants: sulforaphane induces CYP1A2 and other drug-metabolizing enzymes through NRF2, which may alter the metabolism of warfarin and other substrates; monitoring is warranted, Thyroid disease or iodine deficiency: high-dose cruciferous-derived compounds may exert modest goitrogenic effects by competing with iodine uptake; individuals with hypothyroidism or iodine deficiency should exercise caution with very high doses, Prior to surgery: avoid high doses for at least 1 week before elective surgery due to potential effects on platelet function and drug metabolism
Overview
Sulforaphane is formed from glucoraphanin, a glucosinolate stored in cruciferous vegetables, when the plant tissue is disrupted by chewing, chopping, or blending. This disruption brings glucoraphanin into contact with myrosinase, a plant enzyme stored in separate cellular compartments, triggering the hydrolysis that produces sulforaphane. Broccoli sprouts, which are the 3- to 5-day-old seedlings of Brassica oleracea, contain 50 to 100 times more glucoraphanin per gram than mature broccoli florets, making them a far more practical and potent source of sulforaphane. The pharmacological rationale for sulforaphane supplementation rests on a single pivotal mechanism: sulforaphane modifies specific cysteine residues on KEAP1, the cytoplasmic anchor that normally targets the transcription factor NRF2 (NFE2L2) for ubiquitin-proteasome degradation. This modification releases NRF2 from its suppressor, allowing it to translocate to the nucleus and activate over 200 cytoprotective target genes, producing what is arguably the broadest and most powerful endogenous antioxidant and detoxification response that any dietary compound can elicit.
The NRF2 response induced by sulforaphane is qualitatively different from direct antioxidant supplementation. Rather than donating electrons to neutralize individual reactive oxygen species, NRF2 activation upregulates the biosynthetic and recycling enzymes that maintain the cellular antioxidant pools, including glutathione (via GCLC and GCLM induction), thioredoxin (via TXNRD1), and NADPH (via G6PD and ME1). It simultaneously induces NQO1 and other phase 2 detoxification enzymes that conjugate and neutralize electrophilic carcinogens before they can form DNA adducts. The practical consequence of this enzyme induction strategy is that a single dose of sulforaphane triggers a cytoprotective response that lasts 24 to 72 hours, far outlasting the 2 to 3 hour plasma half-life of sulforaphane itself. This prolonged effect is partly explained by the p62-KEAP1-NRF2 positive feedback loop: sulforaphane-induced NRF2 activates SQSTM1/p62 transcription, and the p62 protein physically sequesters KEAP1, preventing it from recycling to suppress NRF2. This self-amplifying loop sustains NRF2 target gene expression well beyond the initial KEAP1 modification.
Beyond NRF2 activation, sulforaphane has a distinct and clinically important mechanism as an HDAC inhibitor. Class I and II histone deacetylases (HDACs) are epigenetic eraser enzymes that remove acetyl groups from histone tails, condensing chromatin and silencing gene expression. In cancer cells, HDAC-mediated silencing of tumor suppressor genes including CDH1 (E-cadherin), CDKN1A (p21), and RB1 is a well-established driver of malignant progression. Sulforaphane and its metabolite erucin inhibit class I and II HDACs at concentrations achievable in human blood after consumption of broccoli sprout extracts, producing dose-dependent increases in histone acetylation and reactivation of silenced tumor suppressor genes in cancer cell lines and in peripheral blood mononuclear cells of human subjects in clinical trials. This epigenetic mechanism operates independently of and is complementary to the NRF2 mechanism, positioning sulforaphane as a dual-mechanism chemopreventive compound.
The hormetic biology of sulforaphane adds a third dimension to its mechanism. Sulforaphane is mildly electrophilic and capable of forming covalent adducts with proteins; this property is what allows it to modify KEAP1 cysteines, but it also means that at modest doses, sulforaphane activates the stress kinase pathways as a mild cellular stressor. This hormetic activation includes HSF1, the master transcription factor for heat shock proteins; NF-kappaB (through the IKK pathway, though sulforaphane typically produces net NF-kappaB inhibition through competing NRF2 cross-talk); and the unfolded protein response. The net effect of this mild hormetic stress is the priming of multiple stress response programs simultaneously, preparing the cell for subsequent proteotoxic, oxidative, or genotoxic challenges. This hormetic framing explains the apparent paradox that sulforaphane, as a mild electrophilic stressor, produces protective effects against more severe oxidative and genotoxic stressors.
Gene Interactions
Key Gene Targets
CDH1
Sulforaphane, derived from broccoli sprouts, inhibits class I and II HDACs and has been reported to restore epigenetically silenced CDH1 (E-cadherin) expression in cancer cell models; HDAC inhibition by sulforaphane increases histone H3 acetylation at the CDH1 promoter, partially reversing the epigenetic silencing that drives epithelial-to-mesenchymal transition.
CDKN1A
Sulforaphane, found in broccoli, induces p21 expression (encoded by CDKN1A) through HDAC inhibition and NRF2-dependent mechanisms, increasing histone acetylation at the p21 promoter and promoting natural cell cycle arrest in cells with DNA damage; this HDAC inhibitory activity on CDKN1A represents a key chemopreventive mechanism.
HSF1
Sulforaphane is the most studied natural HSF1 activator, acting as a mild hormetic electrophilic stressor that modifies HSP90 and other chaperones, releasing sequestered HSF1 to trimerize and activate heat shock gene transcription; this hormetic priming of the heat shock response prepares cells for subsequent proteotoxic challenges.
NFE2L2
Sulforaphane, found at high concentrations in broccoli sprouts, is the most potent natural activator of NRF2 (NFE2L2); it covalently modifies key cysteine residues on KEAP1 (Cys151, Cys273, Cys288), disrupting the KEAP1-NRF2 interaction and allowing NRF2 to escape ubiquitin-proteasome degradation and accumulate in the nucleus to activate over 200 cytoprotective target genes.
NQO1
Sulforaphane is the most potent natural activator of the NRF2-NQO1 pathway; it robustly induces NQO1 (NAD(P)H:quinone oxidoreductase 1) transcription through NRF2-ARE binding, and human clinical trials have confirmed that broccoli sprout extract consumption produces measurable increases in NQO1 enzyme activity in peripheral blood mononuclear cells and in tissue biopsies from multiple organ sites.
SQSTM1
Sulforaphane is a potent NRF2 activator that engages the p62 (SQSTM1)-KEAP1-NRF2 positive feedback loop; NRF2 activation by sulforaphane induces SQSTM1/p62 expression, and p62 protein then sequesters KEAP1, preventing it from recycling to suppress NRF2 and thereby amplifying and sustaining the initial NRF2 response beyond the sulforaphane plasma half-life.
Safety & Dosing
Contraindications
Individuals on anticoagulants: sulforaphane induces CYP1A2 and other drug-metabolizing enzymes through NRF2, which may alter the metabolism of warfarin and other substrates; monitoring is warranted
Thyroid disease or iodine deficiency: high-dose cruciferous-derived compounds may exert modest goitrogenic effects by competing with iodine uptake; individuals with hypothyroidism or iodine deficiency should exercise caution with very high doses
Prior to surgery: avoid high doses for at least 1 week before elective surgery due to potential effects on platelet function and drug metabolism
Drug Interactions
Chemotherapy: NRF2 activation by sulforaphane may theoretically reduce the efficacy of some chemotherapy agents that rely on oxidative stress for their cytotoxic mechanism; clinical relevance is uncertain but caution is warranted during active cancer treatment
CYP1A2 substrates (theophylline, clozapine, caffeine): sulforaphane-mediated NRF2 induction can upregulate CYP1A2, potentially accelerating the metabolism of these drugs and reducing their plasma levels
Other HDAC inhibitors: additive HDAC inhibitory effects may occur when combined with pharmaceutical HDAC inhibitors such as vorinostat or romidepsin; avoid concurrent use without medical supervision
Antithyroid medications: potential additive goitrogenic effects at high doses; avoid combining with methimazole or propylthiouracil without monitoring
Common Side Effects
GI discomfort (bloating, nausea, flatulence) is common at higher doses and relates to the cruciferous vegetable source; taking with food and starting at lower doses reduces GI side effects
Temporary sulfurous body odor and breath from sulforaphane metabolites (including erucin and iberin); this resolves after discontinuation
Studied Doses
Clinical trials have used 10 to 40 mg sulforaphane per day (equivalent to approximately 200 to 400 mg broccoli sprout extract standardized to 10 percent sulforaphane). Glucoraphanin doses of 50 to 200 mg per day have been used in longer trials. Short-term doses up to 200 mg sulforaphane equivalent per day have been well tolerated. Most trials are 1 to 12 weeks; long-term safety data beyond 6 months at high doses is limited.
Mechanism of Action
The NRF2 activation mechanism of sulforaphane triggers a broad transcriptional response that encompasses multiple protective systems. NQO1 (NAD(P)H:quinone oxidoreductase 1) is induced to detoxify quinone electrophiles; HMOX1 (heme oxygenase 1) is induced to generate the anti-inflammatory and cytoprotective metabolites bilirubin and carbon monoxide; GCLC and GCLM (glutamate-cysteine ligase subunits) are induced to increase glutathione biosynthesis; TXNRD1 is induced to support thioredoxin recycling; and a family of glutathione S-transferases (GSTs) is induced to conjugate electrophilic carcinogens and prepare them for biliary excretion. This enzyme induction strategy is fundamentally more durable than direct antioxidant supplementation because the induced enzymes continue functioning for 24 to 72 hours after sulforaphane is cleared from the body. The p62-KEAP1-NRF2 positive feedback loop sustains the response: NRF2 activates SQSTM1/p62 transcription, and p62 protein physically sequesters KEAP1 in autophagosomal cargo, preventing it from recycling to suppress NRF2 and thereby maintaining the activated state.
The HDAC inhibitory mechanism of sulforaphane operates in parallel with and independently of NRF2 activation. Sulforaphane and its metabolite erucin inhibit class I (HDAC1, 2, 3, 8) and class II HDACs at concentrations of 3 to 10 micromolar, which are achievable in human blood after consumption of standardized broccoli sprout extracts. HDAC inhibition increases the acetylation of histone H3 and H4 at specific gene promoters, reactivating epigenetically silenced genes. In cancer cells, where tumor suppressor genes including CDH1, CDKN1A, and RB1 are frequently silenced by HDAC-dependent chromatin condensation, sulforaphane treatment restores expression of these growth-suppressive genes. Human clinical trials have confirmed that broccoli sprout extract consumption produces measurable increases in histone acetylation in peripheral blood mononuclear cells, validating the HDAC inhibitory mechanism in vivo at dietary doses.
Clinical Evidence
The human clinical evidence for sulforaphane spans cancer chemoprevention, pulmonary protection, and carcinogen detoxification. The most compelling clinical study is the Kensler et al. 2012 randomized trial in Qidong, China, where daily broccoli sprout beverage consumption over 12 weeks produced a 61 percent increase in urinary benzene mercapturic acid excretion compared to placebo, demonstrating that NRF2-driven phase 2 enzyme induction by sulforaphane measurably accelerates carcinogen elimination in humans in a high-exposure environment. Studies in asthma patients have shown that broccoli sprout extract reduces nasal lavage inflammatory cytokines and inhibits allergen-driven eosinophilia. Trials in smokers have shown reductions in urinary aflatoxin-DNA adducts, consistent with upregulation of the enzymes that detoxify aflatoxin before DNA damage occurs. NQO1 enzyme activity induction in blood cells has been consistently confirmed across multiple trials and represents the most reproducible pharmacodynamic marker of sulforaphane biological activity in humans. The overall clinical evidence positions sulforaphane as the most translatable natural compound for NRF2-based chemopreventive and cytoprotective strategies.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Landmark study establishing sulforaphane as the principal inducer of phase 2 detoxification enzymes in broccoli, identifying its ability to induce NQO1 and other protective enzymes at nanomolar concentrations and demonstrating inhibition of mammary tumor formation in rat models; this paper initiated the modern field of sulforaphane research.
Pivotal study demonstrating that sulforaphane inhibits class I and II HDACs at concentrations achievable in human blood after broccoli sprout consumption, producing measurable increases in global histone acetylation in normal and cancer cells and establishing the HDAC inhibitory mechanism as a second major chemopreventive pathway distinct from NRF2 activation.
Randomized clinical trial in 291 participants in Qidong, China, demonstrating that broccoli sprout beverage consumption over 12 weeks accelerated the urinary excretion of benzene and acrolein metabolites by 61 and 23 percent respectively, providing direct clinical evidence that NRF2-driven phase 2 enzyme induction by sulforaphane enhances carcinogen detoxification in humans.
In vivo study demonstrating that dietary sulforaphane inhibits HDAC activity in the colon of Apc-deficient mice, increases histone H3 and H4 acetylation at the p21 and Bax promoters, and significantly reduces colon tumor formation; this was the first demonstration that dietary sulforaphane can produce HDAC inhibitory effects in intact mammalian tissues.
Clinical study demonstrating that topical application of broccoli sprout extract to human skin induces NQO1 and other NRF2 target enzymes in a dose-dependent manner and protects against UV-induced erythema and inflammation, confirming that sulforaphane-mediated NRF2 activation is pharmacologically active in human tissues at relevant doses.